Program
Summary
Dr. Braunstein
is Co-investigator in the EDIC trial, a follow-up study
of the Diabetes Control and Complications Cohort looking
at the progression of complications. Complications of diabetes,
especially the long-term effects of diabetes on neuropathy,
retinopathy and nephropathy and interventions that will
prevent or slow progression of these complications.
Dr.
Braunstein
Principal
investigator
in
a
clinical
trail
studying
the
effects
of
a
new
adlose-reductase
inhibitor,
zenarestat,
on
the
rpogression
of
diabetic
neuropathy.
Other
clinical
trials
in
progress
include
the
use
of
inhaled
insulin
in
type
2
diabetes,
new
insulin
senstizing
agents
as
monotherapy
and
in
combination
therapy
in
tpye
2
diabetes,
and
the
use
of
new
insulin
analogues
in
the
treatment
of
type
1
and
type
2
diabetes.
